Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain

NCT00587626 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-06-25

No results posted yet for this study

Summary

The purpose of the proposed study is to evaluate the efficacy of the InterX 5000 in relieving chronic neck and shoulder pain. This study will focus on the efficacy of treating patients who have functional limitations in activity because of chronic/recurrent neck or shoulder pain.

H1: InterX therapy will have a moderate effect to reduce pain.

H2: Functional gains will be greater in patients receiving InterX therapy compared to those who received placebo treatment.

H3: Chronic neck and shoulder pain is more prevalent in patients who exhibit radiographic evidence of degenerative spondylosis/arthrosis of the cervical spine.

Conditions

  • Neck Pain
  • Shoulder Pain
  • Cervical Pain

Interventions

DEVICE

Inactive InterX 5000

Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.

DEVICE

InterX 5000 Treatment

Patients will receive will receive InterX treatment 3 times a week for 4 weeks.

Sponsors & Collaborators

  • Canadian Memorial Chiropractic College

    collaborator OTHER
  • Neuro Resource Group

    collaborator INDUSTRY
  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Linda J Woodhouse, PhD · McMaster University

  • John J Triano, DC, PhD · Canadian Memorial Chiropractic College

  • Vickie Galea, PhD · McMaster University

  • H Stephen Injeyan, PhD, DC · Canadian Memorial Chiropractic College

  • Joy MacDermid, PhD · McMaster University

  • Marion McGregor, DC, PhD · Canadian Memorial Chiropractic College

  • Michael Pierrynowski, PhD · McMaster University

  • Richard Ruegg, PhD, DC · Canadian Memorial Chiropractic College

  • Julita A Teodorczyk-Injeyan, PhD · Canadian Memorial Chiropractic College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-08-31
Completion
2009-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587626 on ClinicalTrials.gov